Targeted, oral agent Enzastaurin shows favorable results
...were gathered from a multicenter Phase II study of enzastaurin as a second- or third-line treatment of NSCLC (ASC...logy platform leader for Lilly. Our objective with enzastaurin is to continue investigating the efficacy and safety of this unique molecule in order to determine t...Making science personal: Lilly Oncology to unveil 76 studies at ASCO 2007
...Enzastaurin Phase II Data of Targeted, Oral Agent enzastaurin in Second- & Third-line NSCLC Abstract # 7543: June 2, 2007; 8:00 a.m. A phase II study of enzastaurin as second- or third-line treatment of non-small cell lung cancer (NSCLC) ...